ADCT_OUT_1 [2025-04-29 08:31:56 -0400] 6123 Bytes | 1662 tokens | Cum: 1662 tkns (20.77% of 8k)
==========================================================================

Hearken to the bells of 8:31 AM on Tue Apr 29, 2025, for ADC Therapeutics SA (ADCT) stirreth—ascending from $1.33 to $1.46. Shall we strike whilst the iron is hot, or bide our time in patience?

--- COMPANY PROFILE ---
Company: ADC Therapeutics SA (ADCT)
IPO: 2020-05-15 (4 Years Ago)
Market Cap: $116,918,929
Shares Outstanding: 99,180,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNYS
Description: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Here’s a list of headlines for ADC Therapeutics SA:

Apr-28-25 10:00AM - ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apr-28-25 10:00AM 07:00AM - ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
Apr-01-25 04:05PM - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Apr-01-25 04:05PM 07:15AM - ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Mar-31-25 09:00PM - ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...
Mar-27-25 11:17AM - ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript
Mar-27-25 11:17AM 08:35AM - ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
Mar-27-25 11:17AM 07:30AM - ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
Mar-25-25 05:30PM - ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
Mar-24-25 11:08PM - ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Mar-20-25 07:15AM - ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
Feb-03-25 04:05PM - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Jan-30-25 07:15AM - ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Jan-02-25 04:05PM - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Dec-30-24 04:30PM - ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
Dec-11-24 07:30AM - ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Dec-09-24 07:30AM - ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
Dec-06-24 07:30AM - ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Dec-02-24 04:30PM - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Nov-14-24 02:02AM - BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...
Nov-08-24 01:14PM - ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
Nov-07-24 08:50AM - ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-10-31T16:57:00Z - Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030
B2 - 2024-08-06T22:51:00Z - ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
B3 - 2024-07-12T10:40:19Z - Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire
B4 - 2024-07-02T16:27:00Z - ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
B5 - 2024-06-27T16:23:00Z - ADC Therapeutics tritt demnächst den Indizes Russell 2000® und Russell 3000® bei
B6 - 2024-06-27T11:15:00Z - ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ADC Therapeutics SA (ADCT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ADCT_OUT_3 [2025-04-29 08:31:57 -0400] 1036 Bytes | 265 tokens | Cum: 1929 tkns (24.11% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/10/31/2972897/28124/en/Cancer-Antibody-Drug-Conjugates-Market-Drugs-Approval-Clinical-Trials-Report-2024-A-US-50-Billion-Market-Opportunity-By-2030.htmlThe global cancer antibody drug conjugates market is a rapidly evolving segment of the cancer therapeutics landscape, with 16 approved products and a market opportunity exceeding $50 billion by 2030. The market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancer types, particularly lung cancer and breast cancer.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_5 [2025-04-29 08:31:58 -0400] 856 Bytes | 255 tokens | Cum: 2186 tkns (27.32% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-05T11:54:25Z - HC Wainwright Analysts Boost Earnings Estimates for ADCT...
A2 - 2025-04-05T08:08:59Z - RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)...
A3 - 2025-04-04T15:20:32Z - Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 14.0%...
A4 - 2025-04-01T20:05:00Z - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan...
A5 - 2025-04-01T20:05:00Z - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADCT_OUT_7 [2025-04-29 08:31:59 -0400] 1181 Bytes | 330 tokens | Cum: 2518 tkns (31.47% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**HC Wainwright Analysts Boost Earnings Estimates for ADCT**Date: 2025-04-05Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/hc-wainwright-analysts-boost-earnings-estimates-for-adct-2025-04-03/ADC Therapeutics SA (NYSE:ADCT - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of ADC Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per share for the quarter, up from their previous estimate of ($0.41). HC Wainwright currently has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics' Q2 2025 earnings at ($0.40) EPS,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_9 [2025-04-29 08:32:00 -0400] 1181 Bytes | 321 tokens | Cum: 2841 tkns (35.51% of 8k)
==========================================================================

Showing A1 (chunk 2 of 6): Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $19.00 million for the quarter, compared to analyst estimates of $19.01 million.

Several other research firms have also weighed in on ADCT. Cantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a report on Friday, March 7th. Guggenheim dropped their price objective on ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Monday. Finally, Stephens boosted their target price on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a res

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_11 [2025-04-29 08:32:01 -0400] 1181 Bytes | 306 tokens | Cum: 3149 tkns (39.36% of 8k)
==========================================================================

Showing A1 (chunk 3 of 6): earch note on Monday, February 24th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ADC Therapeutics currently has a consensus rating of "Buy" and an average target price of $7.75.

Read Our Latest Research Report on ADCT

ADC Therapeutics stock opened at $1.36 on Thursday. The firm has a market capitalization of $131.01 million, a price-to-earnings ratio of -0.57 and a beta of 1.51. The company's 50 day simple moving average is $1.64 and its 200 day simple moving average is $2.22. ADC Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $5.38.

A number of institutional investors and hedge funds have recently bought and sold shares of ADCT. Kazazian Asset Management LLC acquired a new position in shares of ADC Therapeutics during the 4th quarter worth $26,000. Two Sigma Securities LLC bought a new stake in ADC Therapeutics in th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_13 [2025-04-29 08:32:02 -0400] 1181 Bytes | 272 tokens | Cum: 3423 tkns (42.79% of 8k)
==========================================================================

Showing A1 (chunk 4 of 6): e fourth quarter worth approximately $30,000. Russell Investments Group Ltd. boosted its stake in ADC Therapeutics by 122.6% during the fourth quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company's stock worth $33,000 after acquiring an additional 9,248 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of ADC Therapeutics during the fourth quarter valued at approximately $35,000. Finally, Intech Investment Management LLC acquired a new position in ADC Therapeutics during the third quarter worth $41,000. Institutional investors and hedge funds own 41.10% of the company's stock.

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_15 [2025-04-29 08:32:02 -0400] 1181 Bytes | 249 tokens | Cum: 3674 tkns (45.92% of 8k)
==========================================================================

Showing A1 (chunk 5 of 6): , received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider ADC Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.

While ADC Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_17 [2025-04-29 08:32:03 -0400] 307 Bytes | 89 tokens | Cum: 3765 tkns (47.06% of 8k)
==========================================================================

Showing A1 (chunk 6 of 6): stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_19 [2025-04-29 08:32:03 -0400] 1053 Bytes | 284 tokens | Cum: 4051 tkns (50.64% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our audited CONS financial statements, including the no...

S2 - 2025-03-27 8-K Item 2.02. Results of Oper and Fin Cond.

On March 27, 2025, ADC Therapeutics SA (the Company) issued a press release announcing the Companys financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached as Ex...

S8 - 2024-11-07 10-Q PART I: FIN INFO

Item 1. Fin Stmnts

COND CONS BAL SHEETS

(Unaudited)

(in thousands, except share amounts)

September 30, 2024 December 31, 2023 ASSETS Curr assets Cash and cash equiv

$ 274,272 $ 278,598 Accounts receiva...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADCT_OUT_21 [2025-04-29 08:32:04 -0400] 1181 Bytes | 234 tokens | Cum: 4287 tkns (53.59% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements, including the notes thereto, included in this Annual Report. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements. See Forward-Looking Statements.

Overview

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. We have a validated and differentiated technology platform

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_23 [2025-04-29 08:32:05 -0400] 1181 Bytes | 245 tokens | Cum: 4534 tkns (56.67% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): with multiple payloads, linkers and conjugation chemistry, enabling the design of next-generation potent ADCs with an enhanced therapeutic index. Our strategy is focused on expanding and maximizing the ZYNLONTA opportunity in hematology and pursuing our early-stage research portfolio in solid tumors. We are a pioneer and leader in the ADC field with specialized end-to-end capabilities for developing optimized ADCs. This includes a strong, integrated research development organization and a validated technology platform with clinical-stage product candidates currently in the pipeline, multiple next-generation ADCs being developed and a proven executional track record that includes ZYNLONTA, the first PBD-based ADC receiving accelerated approval from the FDA, conditional approval from the European Commission and conditional approval from the NMPA in China for the treatment of relapsed or r

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_25 [2025-04-29 08:32:06 -0400] 1181 Bytes | 288 tokens | Cum: 4824 tkns (60.30% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): efractory DLBCL after two or more lines of systemic therapy.

In our hematology program, our flagship product, ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration (FDA) conditional approval from the European Commission and

conditional approval from the NMPA for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are seeking to continue expanding ZYNLONTA internationally, and into earlier lines of DLBCL and indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL), as a single agent and in combination through our LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial as well as through investigator-initiated trials (IITs) at leading institutions. In addition, we are investigating a CD-22 targeted compound, ADCT-602, in collaboration with t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_27 [2025-04-29 08:32:06 -0400] 1181 Bytes | 280 tokens | Cum: 5106 tkns (63.82% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): he MD Anderson Cancer Center in a Phase 1/2 IIT in relapsed or refractory B-cell acute lymphoblastic leukemia.

In our solid tumor program, we have early stage preclinical research programs, including a portfolio of next-generation investigational ADCs targeting Claudin-6, PSMA, NaPi2b, and ASCT2, the most advanced of which are PSMA and Claudin-6. In addition, we are advancing research with a range of payloads, linkers and conjugation technologies against undisclosed targets. The Company is seeking to maximize the value of its solid tumor program through strategic partnerships, collaborations and license arrangements for one or more of its research programs.

Results of Operations

The following table summarizes our results of operations for the years ended December 31, 2024 and 2023:

##TABLE_START Year Ended December 31, (in thousands, except percentages and per share) 2024 2023 Ch

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_29 [2025-04-29 08:32:07 -0400] 1181 Bytes | 436 tokens | Cum: 5544 tkns (69.30% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ange % Change Revenue Product revenues, net $ 69,280 $ 69,060 $ 220 0.3 % License revenues and royalties 1,557 498 1,059 212.7 % Total revenue, net 70,837 69,558 1,279 1.8 % Operating expense Cost of product sales (5,949) (2,529) (3,420) 135.2 % Research and development (109,633) (127,127) 17,494 (13.8) % Selling and marketing (44,015) (57,464) 13,449 (23.4) % General and administrative (41,894) (48,424) 6,530 (13.5) % Total operating expense (201,491) (235,544) 34,053 (14.5) % Loss from operations (130,654) (165,986) 35,332 (21.3) % Other income (expense) Interest income 12,272 10,540 1,732 16.4 % Interest expense (50,211) (46,325) (3,886) 8.4 % Other, net 12,457 6,352 6,105 96.1 % Total other expense, net (25,482) (29,433) 3,951 (13.4) % Loss before income taxes (156,136) (195,419) 39,283 (20.1) % Income tax expense (166) (39,106) 38,940 (99.6) % Loss before equity in net losses of joi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_31 [2025-04-29 08:32:08 -0400] 790 Bytes | 245 tokens | Cum: 5791 tkns (72.39% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): nt venture (156,302) (234,525) 78,223 (33.4) % Equity in net losses of joint venture (1,544) (5,528) 3,984 (72.1) % Net loss $ (157,846) $ (240,053) $ 82,207 (34.2) % Net loss per share, basic and diluted $ (1.62) $ (2.94) $ 1.32 (44.9) % ##TABLE_END

Revenue

Product Revenues, net

We generate product revenue through the sale of ZYNLONTA in the United States. Revenue is recognized when control is transferred to the customer at the net selling price, which includes reductions for gross-to-net (GTN...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADCT_OUT_33 [2025-04-29 08:32:13 -0400] 6778 Bytes | 1834 tokens | Cum: 7627 tkns (95.34% of 8k)
==========================================================================

This is our set of metrics for ADC Therapeutics SA.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 410,037 | Perf Month: -3.95% | Option/Short: Yes / Yes | Sales Y/Y TTM: 1.84% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 383.13K | Perf Quarter: -13.10% | Short Float: 5.82% | ROE: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.02 | Index: RUT | Short Ratio: 11.83 | ROI: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 56.80 | Market Cap: 144.80M | Short Interest: 4.53M | Sales Surprise: -11.03% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.11 | Shs Outstand: 98.86M | Beta: 1.53 | EPS Surprise: 29.56% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 16.75% | Shs Float: 77.88M | Sales Q/Q: 0.71% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -3.32% | Inst Own: 55.30% | Sales past 5Y: 70.77% | Earnings: Mar 27 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -38.13% | Insider Own: 21.47% | Employees: 265 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 18.70% | Insider Trans: 0.83% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by ADC Therapeutics SA officers or majority shareholders (if available).

Inside Trans: ADC Therapeutics SA (ADCT) by MALLIK AMEET (Chief Executive Officer) on 2025-02-13
- Common Shares: 650000 shares at $1.61 (D)

Inside Trans: ADC Therapeutics SA (ADCT) by Carmona Jose (Chief Financial Officer) on 2025-02-13
- Common Shares: 240000 shares at $1.61 (D)

Inside Trans: ADC Therapeutics SA (ADCT) by Kallebo Lisa Michelle (Chief Accounting Officer) on 2025-02-13
- Common Shares: 41900 shares at $1.61 (D)

Inside Trans: ADC Therapeutics SA (ADCT) by Zaki Mohamed (Chief Medical Officer) on 2025-02-13
- Common Shares: 230000 shares at $1.61 (D)

Inside Trans: ADC Therapeutics SA (ADCT) by GRAHAM PETER J (Chief Legal Officer) on 2025-02-13
- Common Shares: 220000 shares at $1.61 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 70837000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -157846000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.46
Average Volume: 340920.6
30-Day High: 1.46
30-Day Low: 1.1

[Detailed Financials: TTM 2024]
- Total Assets: $321,980,000.00
- Total Liabilities: $524,622,000.00
- Total Equity: $-202,642,000.00
- Current Assets: $307,390,000.00
- Current Liabilities: $80,469,000.00

[Income Statement: TTM 2024]
- Revenue: $70,837,000.00
- Net Income: $-157,846,000.00
- Gross Profit: $64,888,000.00
- Operating Income: $-130,654,000.00
- Earnings Per Share (EPS): -1.62

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-27,731,000.00

[Detailed Financials: FY 2024]
- Total Assets: $321,980,000.00
- Total Liabilities: $524,622,000.00
- Total Equity: $-202,642,000.00
- Current Assets: $307,390,000.00
- Current Liabilities: $80,469,000.00

[Income Statement: FY 2024]
- Revenue: $70,837,000.00
- Net Income: $-157,846,000.00
- Gross Profit: $64,888,000.00
- Operating Income: $-130,654,000.00
- Earnings Per Share (EPS): -1.62

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-27,731,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ADC Therapeutics SA (ADCT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ADC Therapeutics SA.

2) MARKET_SCORE[]
This conversation was initiated because ADCT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ADCT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ADCT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ADCT to increase 50% from its current price of $1.22, say: PRICE_TARGET[1.83]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ADC Therapeutics SA.

11) ETHICAL_RATING[]
Rate ADC Therapeutics SA’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ADC Therapeutics SA.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ADCT_IN_35 [2025-04-29 08:32:14 -0400] 126 Bytes | 29 tokens | Cum: 7866 tkns (98.32% of 8k)
==========================================================================

====================================
[2025-04-29 08:32:14] # Analysis Completed
Elapsed Time: 17.81 seconds